Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year
Identifieur interne : 000094 ( Istex/Corpus ); précédent : 000093; suivant : 000095Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year
Auteurs : D. S. Adnan Majid ; Diederick Stoffers ; Sarah Sheldon ; Samar Hamza ; Wesley K. Thompson ; Jody Goldstein ; Jody Corey-Bloom ; Adam R. AronSource :
- Movement Disorders [ 0885-3185 ] ; 2011-07.
English descriptors
- KwdEn :
Abstract
Intense efforts are underway to evaluate neuroimaging measures as biomarkers for neurodegeneration in premanifest Huntington's disease (preHD). We used a completely automated longitudinal analysis method to compare structural scans in preHD individuals and controls. Using a 1‐year longitudinal design, we analyzed T1‐weighted structural scans in 35 preHD individuals and 22 age‐matched controls. We used the SIENA (Structural Image Evaluation, using Normalization, of Atrophy) software tool to yield overall percentage brain volume change (PBVC) and voxel‐level changes in atrophy. We calculated sample sizes for a hypothetical disease‐modifying (neuroprotection) study. We found significantly greater yearly atrophy in preHD individuals versus controls (mean PBVC controls, −0.149%; preHD, −0.388%; P = .031, Cohen's d = .617). For a preHD subgroup closest to disease onset, yearly atrophy was more than 3 times that of controls (mean PBVC close‐to‐onset preHD, −0.510%; P = .019, Cohen's d = .920). This atrophy was evident at the voxel level in periventricular regions, consistent with well‐established preHD basal ganglia atrophy. We estimated that a neuroprotection study using SIENA would only need 74 close‐to‐onset individuals in each arm (treatment vs placebo) to detect a 50% slowing in yearly atrophy with 80% power. Automated whole‐brain analysis of structural MRI can reliably detect preHD disease progression in 1 year. These results were attained with a readily available imaging analysis tool, SIENA, which is observer independent, automated, and robust with respect to image quality, slice thickness, and different pulse sequences. This MRI biomarker approach could be used to evaluate neuroprotection in preHD. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23656
Links to Exploration step
ISTEX:513EB143EAF43F3EE6C748913627587EA86F73BDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year</title><author><name sortKey="Majid, D S Adnan" sort="Majid, D S Adnan" uniqKey="Majid D" first="D. S. Adnan" last="Majid">D. S. Adnan Majid</name><affiliation><mods:affiliation>Department of Psychology, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurosciences Graduate Program, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Stoffers, Diederick" sort="Stoffers, Diederick" uniqKey="Stoffers D" first="Diederick" last="Stoffers">Diederick Stoffers</name><affiliation><mods:affiliation>Netherlands Institute for Neuroscience, Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Sheldon, Sarah" sort="Sheldon, Sarah" uniqKey="Sheldon S" first="Sarah" last="Sheldon">Sarah Sheldon</name><affiliation><mods:affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Hamza, Samar" sort="Hamza, Samar" uniqKey="Hamza S" first="Samar" last="Hamza">Samar Hamza</name><affiliation><mods:affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Thompson, Wesley K" sort="Thompson, Wesley K" uniqKey="Thompson W" first="Wesley K." last="Thompson">Wesley K. Thompson</name><affiliation><mods:affiliation>Department of Psychiatry, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Goldstein, Jody" sort="Goldstein, Jody" uniqKey="Goldstein J" first="Jody" last="Goldstein">Jody Goldstein</name><affiliation><mods:affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Corey Loom, Jody" sort="Corey Loom, Jody" uniqKey="Corey Loom J" first="Jody" last="Corey-Bloom">Jody Corey-Bloom</name><affiliation><mods:affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Aron, Adam R" sort="Aron, Adam R" uniqKey="Aron A" first="Adam R." last="Aron">Adam R. Aron</name><affiliation><mods:affiliation>Department of Psychology, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurosciences Graduate Program, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:513EB143EAF43F3EE6C748913627587EA86F73BD</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23656</idno><idno type="url">https://api.istex.fr/document/513EB143EAF43F3EE6C748913627587EA86F73BD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000094</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year</title><author><name sortKey="Majid, D S Adnan" sort="Majid, D S Adnan" uniqKey="Majid D" first="D. S. Adnan" last="Majid">D. S. Adnan Majid</name><affiliation><mods:affiliation>Department of Psychology, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurosciences Graduate Program, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Stoffers, Diederick" sort="Stoffers, Diederick" uniqKey="Stoffers D" first="Diederick" last="Stoffers">Diederick Stoffers</name><affiliation><mods:affiliation>Netherlands Institute for Neuroscience, Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Sheldon, Sarah" sort="Sheldon, Sarah" uniqKey="Sheldon S" first="Sarah" last="Sheldon">Sarah Sheldon</name><affiliation><mods:affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Hamza, Samar" sort="Hamza, Samar" uniqKey="Hamza S" first="Samar" last="Hamza">Samar Hamza</name><affiliation><mods:affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Thompson, Wesley K" sort="Thompson, Wesley K" uniqKey="Thompson W" first="Wesley K." last="Thompson">Wesley K. Thompson</name><affiliation><mods:affiliation>Department of Psychiatry, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Goldstein, Jody" sort="Goldstein, Jody" uniqKey="Goldstein J" first="Jody" last="Goldstein">Jody Goldstein</name><affiliation><mods:affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Corey Loom, Jody" sort="Corey Loom, Jody" uniqKey="Corey Loom J" first="Jody" last="Corey-Bloom">Jody Corey-Bloom</name><affiliation><mods:affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Aron, Adam R" sort="Aron, Adam R" uniqKey="Aron A" first="Adam R." last="Aron">Adam R. Aron</name><affiliation><mods:affiliation>Department of Psychology, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurosciences Graduate Program, University of California, San Diego (UCSD), San Diego, California, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-07">2011-07</date><biblScope unit="vol">26</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1481">1481</biblScope><biblScope unit="page" to="1488">1488</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">513EB143EAF43F3EE6C748913627587EA86F73BD</idno><idno type="DOI">10.1002/mds.23656</idno><idno type="ArticleID">MDS23656</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MRI biomarker</term><term>longitudinal atrophy</term><term>premanifest HD</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Intense efforts are underway to evaluate neuroimaging measures as biomarkers for neurodegeneration in premanifest Huntington's disease (preHD). We used a completely automated longitudinal analysis method to compare structural scans in preHD individuals and controls. Using a 1‐year longitudinal design, we analyzed T1‐weighted structural scans in 35 preHD individuals and 22 age‐matched controls. We used the SIENA (Structural Image Evaluation, using Normalization, of Atrophy) software tool to yield overall percentage brain volume change (PBVC) and voxel‐level changes in atrophy. We calculated sample sizes for a hypothetical disease‐modifying (neuroprotection) study. We found significantly greater yearly atrophy in preHD individuals versus controls (mean PBVC controls, −0.149%; preHD, −0.388%; P = .031, Cohen's d = .617). For a preHD subgroup closest to disease onset, yearly atrophy was more than 3 times that of controls (mean PBVC close‐to‐onset preHD, −0.510%; P = .019, Cohen's d = .920). This atrophy was evident at the voxel level in periventricular regions, consistent with well‐established preHD basal ganglia atrophy. We estimated that a neuroprotection study using SIENA would only need 74 close‐to‐onset individuals in each arm (treatment vs placebo) to detect a 50% slowing in yearly atrophy with 80% power. Automated whole‐brain analysis of structural MRI can reliably detect preHD disease progression in 1 year. These results were attained with a readily available imaging analysis tool, SIENA, which is observer independent, automated, and robust with respect to image quality, slice thickness, and different pulse sequences. This MRI biomarker approach could be used to evaluate neuroprotection in preHD. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>D.S. Adnan Majid BS</name><affiliations><json:string>Department of Psychology, University of California, San Diego (UCSD), San Diego, California, USA</json:string><json:string>Neurosciences Graduate Program, University of California, San Diego (UCSD), San Diego, California, USA</json:string></affiliations></json:item><json:item><name>Diederick Stoffers PhD</name><affiliations><json:string>Netherlands Institute for Neuroscience, Amsterdam, The Netherlands</json:string></affiliations></json:item><json:item><name>Sarah Sheldon BS</name><affiliations><json:string>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</json:string></affiliations></json:item><json:item><name>Samar Hamza BS</name><affiliations><json:string>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</json:string></affiliations></json:item><json:item><name>Wesley K. Thompson PhD</name><affiliations><json:string>Department of Psychiatry, University of California, San Diego (UCSD), San Diego, California, USA</json:string></affiliations></json:item><json:item><name>Jody Goldstein BS</name><affiliations><json:string>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</json:string></affiliations></json:item><json:item><name>Jody Corey‐Bloom MD, PhD</name><affiliations><json:string>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</json:string></affiliations></json:item><json:item><name>Adam R. Aron PhD</name><affiliations><json:string>Department of Psychology, University of California, San Diego (UCSD), San Diego, California, USA</json:string><json:string>Neurosciences Graduate Program, University of California, San Diego (UCSD), San Diego, California, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>MRI biomarker</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>premanifest HD</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>longitudinal atrophy</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Intense efforts are underway to evaluate neuroimaging measures as biomarkers for neurodegeneration in premanifest Huntington's disease (preHD). We used a completely automated longitudinal analysis method to compare structural scans in preHD individuals and controls. Using a 1‐year longitudinal design, we analyzed T1‐weighted structural scans in 35 preHD individuals and 22 age‐matched controls. We used the SIENA (Structural Image Evaluation, using Normalization, of Atrophy) software tool to yield overall percentage brain volume change (PBVC) and voxel‐level changes in atrophy. We calculated sample sizes for a hypothetical disease‐modifying (neuroprotection) study. We found significantly greater yearly atrophy in preHD individuals versus controls (mean PBVC controls, −0.149%; preHD, −0.388%; P = .031, Cohen's d = .617). For a preHD subgroup closest to disease onset, yearly atrophy was more than 3 times that of controls (mean PBVC close‐to‐onset preHD, −0.510%; P = .019, Cohen's d = .920). This atrophy was evident at the voxel level in periventricular regions, consistent with well‐established preHD basal ganglia atrophy. We estimated that a neuroprotection study using SIENA would only need 74 close‐to‐onset individuals in each arm (treatment vs placebo) to detect a 50% slowing in yearly atrophy with 80% power. Automated whole‐brain analysis of structural MRI can reliably detect preHD disease progression in 1 year. These results were attained with a readily available imaging analysis tool, SIENA, which is observer independent, automated, and robust with respect to image quality, slice thickness, and different pulse sequences. This MRI biomarker approach could be used to evaluate neuroprotection in preHD. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1762</abstractCharCount><pdfWordCount>5204</pdfWordCount><pdfCharCount>32550</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>253</abstractWordCount></qualityIndicators><title>Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year</title><genre><json:string>Serial article</json:string></genre><host><volume>26</volume><pages><total>8</total><last>1488</last><first>1481</first></pages><issn><json:string>0885-3185</json:string></issn><issue>8</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23656</json:string></doi><id>513EB143EAF43F3EE6C748913627587EA86F73BD</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/513EB143EAF43F3EE6C748913627587EA86F73BD/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/513EB143EAF43F3EE6C748913627587EA86F73BD/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/513EB143EAF43F3EE6C748913627587EA86F73BD/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Relevant conflicts of interest/financial disclosures: This study was supported by the CHDI Foundation. Jody Corey‐Bloom has received research support from the Huntington's Study Group, and Adam R. Aron receives research support from CHDI. Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year</title><author><persName><forename type="first">D.S. Adnan</forename><surname>Majid</surname><roleName type="degree">BS</roleName></persName><affiliation>Department of Psychology, University of California, San Diego (UCSD), San Diego, California, USA</affiliation><affiliation>Neurosciences Graduate Program, University of California, San Diego (UCSD), San Diego, California, USA</affiliation></author><author><persName><forename type="first">Diederick</forename><surname>Stoffers</surname><roleName type="degree">PhD</roleName></persName><affiliation>Netherlands Institute for Neuroscience, Amsterdam, The Netherlands</affiliation></author><author><persName><forename type="first">Sarah</forename><surname>Sheldon</surname><roleName type="degree">BS</roleName></persName><affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</affiliation></author><author><persName><forename type="first">Samar</forename><surname>Hamza</surname><roleName type="degree">BS</roleName></persName><affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</affiliation></author><author><persName><forename type="first">Wesley K.</forename><surname>Thompson</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Psychiatry, University of California, San Diego (UCSD), San Diego, California, USA</affiliation></author><author><persName><forename type="first">Jody</forename><surname>Goldstein</surname><roleName type="degree">BS</roleName></persName><affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</affiliation></author><author><persName><forename type="first">Jody</forename><surname>Corey‐Bloom</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</affiliation></author><author><persName><forename type="first">Adam R.</forename><surname>Aron</surname><roleName type="degree">PhD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Psychology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093‐0109, USA</p></note><affiliation>Department of Psychology, University of California, San Diego (UCSD), San Diego, California, USA</affiliation><affiliation>Neurosciences Graduate Program, University of California, San Diego (UCSD), San Diego, California, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-07"></date><biblScope unit="vol">26</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1481">1481</biblScope><biblScope unit="page" to="1488">1488</biblScope></imprint></monogr><idno type="istex">513EB143EAF43F3EE6C748913627587EA86F73BD</idno><idno type="DOI">10.1002/mds.23656</idno><idno type="ArticleID">MDS23656</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Intense efforts are underway to evaluate neuroimaging measures as biomarkers for neurodegeneration in premanifest Huntington's disease (preHD). We used a completely automated longitudinal analysis method to compare structural scans in preHD individuals and controls. Using a 1‐year longitudinal design, we analyzed T1‐weighted structural scans in 35 preHD individuals and 22 age‐matched controls. We used the SIENA (Structural Image Evaluation, using Normalization, of Atrophy) software tool to yield overall percentage brain volume change (PBVC) and voxel‐level changes in atrophy. We calculated sample sizes for a hypothetical disease‐modifying (neuroprotection) study. We found significantly greater yearly atrophy in preHD individuals versus controls (mean PBVC controls, −0.149%; preHD, −0.388%; P = .031, Cohen's d = .617). For a preHD subgroup closest to disease onset, yearly atrophy was more than 3 times that of controls (mean PBVC close‐to‐onset preHD, −0.510%; P = .019, Cohen's d = .920). This atrophy was evident at the voxel level in periventricular regions, consistent with well‐established preHD basal ganglia atrophy. We estimated that a neuroprotection study using SIENA would only need 74 close‐to‐onset individuals in each arm (treatment vs placebo) to detect a 50% slowing in yearly atrophy with 80% power. Automated whole‐brain analysis of structural MRI can reliably detect preHD disease progression in 1 year. These results were attained with a readily available imaging analysis tool, SIENA, which is observer independent, automated, and robust with respect to image quality, slice thickness, and different pulse sequences. This MRI biomarker approach could be used to evaluate neuroprotection in preHD. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>MRI biomarker</term></item><item><term>premanifest HD</term></item><item><term>longitudinal atrophy</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-09-27">Received</change><change when="2011-01-03">Registration</change><change when="2011-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/513EB143EAF43F3EE6C748913627587EA86F73BD/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="80"><doi origin="wiley" registered="yes">10.1002/mds.v26.8</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">8</numbering></numberingGroup><coverDate startDate="2011-07">July 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="190" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23656</doi><idGroup><id type="unit" value="MDS23656"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-09-27"></event><event type="manuscriptRevised" date="2010-11-30"></event><event type="manuscriptAccepted" date="2011-01-03"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText mathml2tex" date="2011-12-15"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-04-11"></event><event type="publishedOnlineFinalForm" date="2011-07-21"></event><event type="firstOnline" date="2011-04-11"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1481</numbering><numbering type="pageLast">1488</numbering></numberingGroup><correspondenceTo>Department of Psychology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093‐0109, USA</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23656.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="42"></count><count type="wordTotal" number="6871"></count></countGroup><titleGroup><title type="main" xml:lang="en">Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year<link href="#fn5"></link></title><title type="short" xml:lang="en">Longitudinal Biomarker in Premanifest HD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>D.S. Adnan</givenNames><familyName>Majid</familyName><degrees>BS</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Diederick</givenNames><familyName>Stoffers</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Sarah</givenNames><familyName>Sheldon</familyName><degrees>BS</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Samar</givenNames><familyName>Hamza</familyName><degrees>BS</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Wesley K.</givenNames><familyName>Thompson</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Jody</givenNames><familyName>Goldstein</familyName><degrees>BS</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Jody</givenNames><familyName>Corey‐Bloom</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Adam R.</givenNames><familyName>Aron</familyName><degrees>PhD</degrees></personName><contactDetails><email>adamaron@ucsd.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychology, University of California, San Diego (UCSD), San Diego, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Neurosciences Graduate Program, University of California, San Diego (UCSD), San Diego, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="NL" type="organization"><unparsedAffiliation>Netherlands Institute for Neuroscience, Amsterdam, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, University of California, San Diego (UCSD), San Diego, California, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">MRI biomarker</keyword><keyword xml:id="kwd2">premanifest HD</keyword><keyword xml:id="kwd3">longitudinal atrophy</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Intense efforts are underway to evaluate neuroimaging measures as biomarkers for neurodegeneration in premanifest Huntington's disease (preHD). We used a completely automated longitudinal analysis method to compare structural scans in preHD individuals and controls. Using a 1‐year longitudinal design, we analyzed T<sub>1</sub>‐weighted structural scans in 35 preHD individuals and 22 age‐matched controls. We used the SIENA (Structural Image Evaluation, using Normalization, of Atrophy) software tool to yield overall percentage brain volume change (PBVC) and voxel‐level changes in atrophy. We calculated sample sizes for a hypothetical disease‐modifying (neuroprotection) study. We found significantly greater yearly atrophy in preHD individuals versus controls (mean PBVC controls, −0.149%; preHD, −0.388%; <i>P</i> = .031, Cohen's d = .617). For a preHD subgroup closest to disease onset, yearly atrophy was more than 3 times that of controls (mean PBVC close‐to‐onset preHD, −0.510%; <i>P</i> = .019, Cohen's d = .920). This atrophy was evident at the voxel level in periventricular regions, consistent with well‐established preHD basal ganglia atrophy. We estimated that a neuroprotection study using SIENA would only need 74 close‐to‐onset individuals in each arm (treatment vs placebo) to detect a 50% slowing in yearly atrophy with 80% power. Automated whole‐brain analysis of structural MRI can reliably detect preHD disease progression in 1 year. These results were attained with a readily available imaging analysis tool, SIENA, which is observer independent, automated, and robust with respect to image quality, slice thickness, and different pulse sequences. This MRI biomarker approach could be used to evaluate neuroprotection in preHD. © 2011 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn5"><p><b>Relevant conflicts of interest/financial disclosures:</b> This study was supported by the CHDI Foundation. Jody Corey‐Bloom has received research support from the Huntington's Study Group, and Adam R. Aron receives research support from CHDI. Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Longitudinal Biomarker in Premanifest HD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year</title></titleInfo><name type="personal"><namePart type="given">D.S. Adnan</namePart><namePart type="family">Majid</namePart><namePart type="termsOfAddress">BS</namePart><affiliation>Department of Psychology, University of California, San Diego (UCSD), San Diego, California, USA</affiliation><affiliation>Neurosciences Graduate Program, University of California, San Diego (UCSD), San Diego, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Diederick</namePart><namePart type="family">Stoffers</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Netherlands Institute for Neuroscience, Amsterdam, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sarah</namePart><namePart type="family">Sheldon</namePart><namePart type="termsOfAddress">BS</namePart><affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Samar</namePart><namePart type="family">Hamza</namePart><namePart type="termsOfAddress">BS</namePart><affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Wesley K.</namePart><namePart type="family">Thompson</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Psychiatry, University of California, San Diego (UCSD), San Diego, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jody</namePart><namePart type="family">Goldstein</namePart><namePart type="termsOfAddress">BS</namePart><affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jody</namePart><namePart type="family">Corey‐Bloom</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurosciences, University of California, San Diego (UCSD), San Diego, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Adam R.</namePart><namePart type="family">Aron</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Psychology, University of California, San Diego (UCSD), San Diego, California, USA</affiliation><affiliation>Neurosciences Graduate Program, University of California, San Diego (UCSD), San Diego, California, USA</affiliation><description>Correspondence: Department of Psychology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093‐0109, USA</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-07</dateIssued><dateCaptured encoding="w3cdtf">2010-09-27</dateCaptured><dateValid encoding="w3cdtf">2011-01-03</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">4</extent><extent unit="references">42</extent><extent unit="words">6871</extent></physicalDescription><abstract lang="en">Intense efforts are underway to evaluate neuroimaging measures as biomarkers for neurodegeneration in premanifest Huntington's disease (preHD). We used a completely automated longitudinal analysis method to compare structural scans in preHD individuals and controls. Using a 1‐year longitudinal design, we analyzed T1‐weighted structural scans in 35 preHD individuals and 22 age‐matched controls. We used the SIENA (Structural Image Evaluation, using Normalization, of Atrophy) software tool to yield overall percentage brain volume change (PBVC) and voxel‐level changes in atrophy. We calculated sample sizes for a hypothetical disease‐modifying (neuroprotection) study. We found significantly greater yearly atrophy in preHD individuals versus controls (mean PBVC controls, −0.149%; preHD, −0.388%; P = .031, Cohen's d = .617). For a preHD subgroup closest to disease onset, yearly atrophy was more than 3 times that of controls (mean PBVC close‐to‐onset preHD, −0.510%; P = .019, Cohen's d = .920). This atrophy was evident at the voxel level in periventricular regions, consistent with well‐established preHD basal ganglia atrophy. We estimated that a neuroprotection study using SIENA would only need 74 close‐to‐onset individuals in each arm (treatment vs placebo) to detect a 50% slowing in yearly atrophy with 80% power. Automated whole‐brain analysis of structural MRI can reliably detect preHD disease progression in 1 year. These results were attained with a readily available imaging analysis tool, SIENA, which is observer independent, automated, and robust with respect to image quality, slice thickness, and different pulse sequences. This MRI biomarker approach could be used to evaluate neuroprotection in preHD. © 2011 Movement Disorder Society</abstract><note type="content">*Relevant conflicts of interest/financial disclosures: This study was supported by the CHDI Foundation. Jody Corey‐Bloom has received research support from the Huntington's Study Group, and Adam R. Aron receives research support from CHDI. Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>MRI biomarker</topic><topic>premanifest HD</topic><topic>longitudinal atrophy</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1481</start><end>1488</end><total>8</total></extent></part></relatedItem><identifier type="istex">513EB143EAF43F3EE6C748913627587EA86F73BD</identifier><identifier type="DOI">10.1002/mds.23656</identifier><identifier type="ArticleID">MDS23656</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000094 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000094 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:513EB143EAF43F3EE6C748913627587EA86F73BD
|texte= Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year
}}
| This area was generated with Dilib version V0.6.23. |  |